Ani Pharmaceuticals (ANIP) Deferred Taxes (2014 - 2026)

Ani Pharmaceuticals has disclosed Deferred Taxes across 13 years of filings, most recently posting $2.5 million for Q1 2026.

• Deferred Taxes for Q1 2026 came in at $2.5 million, up 174.34% year-over-year; the trailing twelve-month figure through Mar 2026 was $20.1 million (up 170.9% YoY), and the FY2025 annual result was $14.2 million, up 164.97% from the prior year.
• Deferred Taxes came in at $2.5 million for Q1 2026 at Ani Pharmaceuticals, up from $2.4 million in the prior quarter.
• In the past five years, Deferred Taxes ranged from a high of $18.8 million in Q3 2025 to a low of -$17.5 million in Q4 2024.
• The 5-year median for Deferred Taxes is -$2.2 million (2022), against an average of -$1.9 million.
• Across the five-year window, Deferred Taxes plunged 2575.27% in 2022 and soared 436.44% in 2025, its largest moves.
• Ani Pharmaceuticals' Deferred Taxes stood at -$1.6 million in 2022, then slumped by 413.6% to -$8.3 million in 2023, then sank by 110.04% to -$17.5 million in 2024, then soared by 113.44% to $2.4 million in 2025, then advanced by 6.75% to $2.5 million in 2026.
• The last three Deferred Taxes figures came in at $2.5 million (Q1 2026), $2.4 million (Q4 2025), and $18.8 million (Q3 2025), per Business Quant data.